Dante Labs selected to provide genetic testing for Abu Dhabi Stem Cells Center, jointly developing mRNA cancer vaccines
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, is pleased to announce the company has been selected as the genetic testing provider for Abu Dhabi Stem Cells Center (ADSCC), the Abu Dhabi-based specialist healthcare center focused on cell therapy and regenerative medicine. In parallel, a joint R&D program has been launched focused on the development of a mRNA vaccine platform to identify individual cancer treatments.
“This collaboration with ADSCC is an important step forward in our strategy to provide the best clinical genetic services now to United Arab Emirates and in the Region. The goal is that partnerships like this will pave the way to a much wider adoption of genomics in additional clinical fields,” said Andrea Riposati, CEO of Dante Labs. “It is clear that the UAE has become a global leader in the field of genomics, and we are pleased to invest in this innovative country.’’
Effective April 18, 2022, Dante has begun providing clinical genetic testing to ADSCC patients covering a wide spectrum of medical specializations and all testing will take place in Dante’s new Dubai laboratory.
“We are very excited and are looking forward to our upcoming collaboration with Dante,” said Dr. Yendry Ventura Carmenate, General Manager at ADSCC. “The combined experience of the professionals at the helm of this collaboration gives us absolute assurance in the success of this very ambitious endeavor. Working together with Dante Labs provides us with an excellent opportunity to further boost the status of United Arab Emirates as the worldwide leader in both genomics and innovative healthcare practices, aimed at the eradication of deadly diseases throughout the world for the greater good of humanity.”
In addition to genomic testing services, Dante and the ADSCC will partner on the launch of an R&D program with a focus on personalized treatments for oncology patients, and eventually the development of cancer vaccines.
"The hope with testing programs like ours with ADSCC is that it will pave the way for wider adoption of genomes in other areas such as R&D and training programs,” said Professor Mattia Capulli, Chief Scientific Officer of Dante Laboratories. “The mRNA technology is extremely promising for infectious diseases. We are convinced that the joint R&D program will deliver solid results in oncology treatments very soon and will lead to new types of vaccines in oncology and other clinical areas.”
About Dante Labs
Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
About Abu Dhabi Stem Cells Center (ADSCC)
Abu Dhabi Stem Cells Center (ADSCC) is an Abu Dhabi-based specialist healthcare center focused on cell therapy and regenerative medicine techniques, as well as delivering cutting-edge research on stem cells in the region.
The Center was founded in March 2019 to meet growing domestic and regional demand for highly specialized medical services and treatments. Equipped with the latest technologies, medical devices which are unique to the region, and a team of internationally recognized doctors working hand in hand with researchers, ADSCC is the first of its kind in the UAE.
The Center focuses primarily on harvesting, processing, characterizing and storing cell products for clinical application in both regenerative medicine and hematopoietic transplantation. It aims to streamline and develop new processes related to stem cell therapy and research, in order to both serve our team of doctors’ clinical needs and become a referral center for the region.
Abu Dhabi Stem Cells Center
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/76811dae-c095-4504-a5b6-34da0ca44892To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Vapers deliver an open letter to Swedish Members of the Parliament and ask to stop the vaping flavour ban25.5.2022 09:10:17 CEST | Press release
Stockholm, Sweden, May 25, 2022 (GLOBE NEWSWIRE) -- Yesterday, the global vaping advocacy group World Vapers Alliance delivered an open letter to the Swedish parliament urging policymakers to stop the flavour ban. World Vapers’ Alliance held another protest today to stand against the ban on vape flavours. The group marched in front of the Parliament with the slogan “Flavours help smokers quit” during parliament's session and delivered an open letter to members of parliament to urge them to vote against the ban. Earlier this year, the Swedish government introduced a bill that would prohibit all non-tobacco vape flavours in nicotine and non-nicotine products. If approved, the bill is set to enter into force on 1 January 2023. “I benefited first hand from vaping and managed to stay smoke free for the last few years. Like most other smokers, I tried to find a way out of cigarettes - but nothing worked for me, the patches, the gums, the inhalers. Vaping - and especially combined with flavou
Kalera - Last day of trading in Kalera AS' shares on Euronext Growth Oslo25.5.2022 08:00:00 CEST | Press release
OSLO, Norway, May 25, 2022 (GLOBE NEWSWIRE) -- Reference is made to the stock exchange announcement published by Kalera AS (the "Company") (Euronext Growth Oslo: KAL, Bloomberg: KSLLF) on 13 May 2022 regarding the merger with its wholly-owned Luxembourg subsidiary Kalera S.A. (the "Merger"). The Merger will become effective upon publication of the minutes from Kalera S.A.'s general meeting approving the Merger in accordance with Luxembourg law. Such publication, and the effectiveness of the Merger, is expected to occur on 27 May 2022 (the "Effectiveness"). The last day of trading in the Company's shares on Euronext Growth Oslo is today, 25 May 2022. A trading suspension will be imposed by the Oslo Stock Exchange following end of trading today, and the trading suspension will remain in force until the Effectiveness. As of the Effectiveness, all of the Company's assets, rights and liabilities will be transferred to Kalera S.A., and the Company will be dissolved and have it shares deliste
Reminder of an Investor Conference Webinar25.5.2022 08:00:00 CEST | Press release
We would like to remind that KN invites shareholders, investors, analysts, and other stakeholders to join its investor conference webinar scheduled on May 27th of 2022 at 9.00 am (EET). The presentation will be held in English. The webinar will be hosted by KN Chief Executive Officer Darius Šilenskis and Chief Financial Officer Mindaugas Kvekšas who will introduce the performance and unaudited financial results of KN for the three months of 2022. How to join the webinar? To join the webinar, please register via following link: https://nasdaq.zoom.us/webinar/register/WN_aVz8e35rRqO1UC5O3WBp4AYou will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to register on the Zoom platform. The webinar will be recorded and available online for everyone at the company’s website on www.kn.lt and on Nasdaq Baltic youtube.com account. What is a corporate webinar? A corporate webinar is a virtual conference, du
Saniona publishes its interim report for the first quarter of 202225.5.2022 08:00:00 CEST | Press release
Q12022 (Q12021) Revenue was SEK 6.6 M (3.4 M)Operating loss was SEK -133.2 M (-94.1 M) Net loss was SEK -133.4 M (-83.4 M)Loss per share was SEK -2.14 (-1.34)Diluted loss per share was SEK -2.14 (-1.34) Business highlights in Q1 2022 Saniona initiated the Multiple Ascending Dose (MAD) stage and the Positron Emission Tomography (PET) stage of its Phase 1 trial of SAN711; The ongoing Phase 1 trial is placebo-controlled, and the data remain blinded. Saniona continues to expect data from the trial by mid-2022.Saniona received SEK 7.3 million (US$0.8 million) from Novartis related to Novartis’s January 2021 acquisition of Cadent Therapeutics, in which Saniona held a 3% ownership stake. This payment, in addition to the previously received SEK 24.2 million (US$2.9 million), together complete Saniona’s portion of the upfront payment connected to the acquisition. Saniona may also receive a portion of the remaining SEK 5.1 billion (US$560 million) in contingent payments associated with the achie
Saniona publicerar sin delårsrapport för det första kvartalet 202225.5.2022 08:00:00 CEST | Pressemelding
Q1 2022 (Q1 2021) Intäkter uppgick till 6,6 MSEK (3,4 M)Rörelseresultat uppgick till -133,2 MSEK (-94,1 M) Periodens resultat uppgick till -133,4 MSEK (-83,4 M)Resultat per aktie uppgick till -2,14 SEK (-1,34)Resultat per aktie efter utspädning uppgick till -2,14 SEK (-1,34) Väsentliga händelser under Q1 2022 Saniona inledde upprepad dosering med doseskalering (MAD) samt undersökningar med positronemissionstomografi (PET) i Fas 1-studien med SAN711; den pågående Fas 1-studien är placebokontrollerad och data är fortfarande blindade. Saniona räknar fortsatt med att få tillgång till data från studien under mitten av 2022.Saniona erhöll 7,3 MSEK (0,8 MUSD) från Novartis relaterat till Novartis förvärv av Cadent Therapeutics i januari 2021, där Saniona hade en ägarandel på 3 procent. Denna betalning, utöver de tidigare erhållna 24,2 MSEK (2,9 MUSD), utgör tillsammans Sanionas del av förskottsbetalningen kopplad till förvärvet. Saniona kan också komma att erhålla en andel av de återstående 5